Carbon Monoxide Linked to Lower Parkinson Risk
Researchers are investigating how low-dose carbon monoxide might offer protective effects against Parkinson's disease.
Updated on Oct. 16, 2026 in Asthma
Live Poll
Should scientists pursue medical therapies derived from isolated components of known harmful substances?
A 2024 study suggests that low-dose carbon monoxide, a component of cigarette smoke, may explain the reduced risk of Parkinson's disease long observed in smokers. This discovery has led to the launch of a Phase 2a clinical trial for a new oral drug designed to leverage these potential neuroprotective benefits.
Why it matters
Understanding this chemical mechanism could provide a breakthrough for the 1.1 million people in the United States currently living with Parkinson's disease. Scientists are working to isolate these protective properties without the severe health risks associated with traditional smoking, which causes 85 percent of lung cancer cases.
A JAMA Neurology study analyzed data from over 500,000 adults, while a 2024 study in npj Parkinson's Disease identified low-dose carbon monoxide as a potential neuroprotective agent.
The players
Edward Roehrig
He is a historical figure known for promoting the health benefits of Thompson's Mell-O-Well cigars.
Oxford University
This is a world-leading research institution where the lead authors of the Parkinson's studies are based.
The details
Low-dose carbon monoxide acts by reducing oxidative stress and inflammation while activating neuroprotective signaling in the brain. Researchers confirmed that while human cells naturally produce small amounts of the gas, the trial aims to replicate these protective effects through therapeutic intervention.
Timeline
1930: Edward Roehrig makes unverified health claims about cigars.
1959: Scientists first observe that regular smokers exhibit lower Parkinson's risk.
2024: A new study links low-dose carbon monoxide to reduced Parkinson's disease risk.
June 2026: A biotech firm initiates a Phase 2a clinical trial for the drug HBI-002.
Health Landscape
This research extends the 1959 observation of lower Parkinson's risk in smokers by finally identifying the specific chemical mechanism responsible. It marks a significant shift from observing epidemiological correlations to testing targeted pharmacological interventions.
Patients should note that while this research is promising, it is strictly part of an early-stage clinical trial for a pharmaceutical candidate. No tobacco-based products or home-based carbon monoxide exposure should ever be used as a medical treatment due to severe toxicity risks.
The takeaway
Science continues to find ways to isolate beneficial compounds from substances historically known for their extreme toxicity. Patients should follow the progression of HBI-002 trials as a potential future therapy for neurodegenerative conditions.
Further reading
Learn more about the latest research on lung health and chemical exposure at Asthma.
Source note: This article includes information reported by Popular Mechanics.
Live Poll
Should scientists pursue medical therapies derived from isolated components of known harmful substances?
